• BriaCell Therapeutics will present new clinical data at 2026 AACR Annual Meeting, including posters on April 19-20.
• Phase 3 study of Bria-IMT with an immune checkpoint inhibitor in heavily pretreated metastatic breast cancer showed quality of life largely preserved during treatment.
• Additional Phase 2 analyses identified blood-based biomarkers that could help predict prognosis or checkpoint inhibitor response in metastatic breast cancer.
• Company positioned the quality-of-life findings as supportive of tolerability in late-line use, a key factor for adoption in patients with limited options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200730PRIMZONEFULLFEED9692782) on April 20, 2026, and is solely responsible for the information contained therein.